Bellicum Pharmaceuticals Announces Closing of Public Offering
30 March 2017 - 10:00PM
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the
closing, on March 29, 2017, of its previously announced
underwritten public offering of 5,750,000 shares of its common
stock, including 750,000 shares sold pursuant to the underwriters’
full exercise of their option to purchase additional shares, at a
public offering price of $12.00 per share. The aggregate offering
size was approximately $69.0 million, before deducting the
underwriting discounts and commissions and other offering expenses.
Citigroup and Jefferies acted as lead book-running managers for
the offering. Guggenheim Securities, Ladenburg Thalmann, Raymond
James and SunTrust Robinson Humphrey acted as co-managers.
The securities described above were offered by Bellicum pursuant
to a shelf registration statement filed by Bellicum with the
Securities and Exchange Commission (SEC), which was declared
effective on February 1, 2016. A final prospectus supplement and
accompanying prospectus relating to the offering have been filed
with the SEC and are available for free on the SEC’s website at
http://www.sec.gov. Copies of the final prospectus supplement and
the accompanying prospectus related to this offering may be
obtained from: Citigroup Global Markets Inc., c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by telephone at (800) 831-9146; or Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by
e-mail at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Bellicum Pharmaceuticals, Inc.
Bellicum is a clinical stage biopharmaceutical company focused
on discovering and developing cellular immunotherapies for cancers
and orphan inherited blood disorders. Bellicum is using its
proprietary Chemical Induction of Dimerization (CID) technology
platform to engineer and control components of the immune system.
Bellicum is developing next-generation product candidates in some
of the most important areas of cellular immunotherapy, including
hematopoietic stem cell transplantation (HSCT), and CAR T and TCR
cell therapies. Bellicum is based in Houston, Texas.
Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO
832-384-1116
amusso@bellicum.com
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2024 to May 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From May 2023 to May 2024